Press

“However, whether it is a newer innovation in imaging, dialysis therapy, mechanical ventilation or circulatory support, nothing has really moved the needle in terms of improved clinical outcomes. These are mainly supportive care technologies that keep the patient alive until they can recover on their own,” said Halpern.

“Our collaboration with CytoSorbents enables us to offer this innovative, easy-to-use blood purification therapy to address our customers’ most challenging cardiac cases,” stated Arik Anderson, President of Perfusion and Surgical Devices Division at Terumo. “CytoSorb integrates with the heart-lung machine platform, giving surgical teams, for the first time, the ability to safely reduce dangerous inflammatory mediators in real-time as they are being generated during cardiac surgery.”

According to the current definition, sepsis is a life-threatening organ dysfunction due to a dysregulated body response to an infection. This systemic infection can be caused by bacteria, fungi or even viruses.

In this study, clinical researchers at Maasstad Hospital and at Erasmus University Medical Center in Rotterdam, Netherlands conducted a retrospective evaluation of 116 patients with septic shock, who required vasopressors to increase their blood pressure, and renal replacement therapy (RRT) due to kidney failure.

Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, „I am happy to announce CytoSorbents successfully completed its CE Mark and ISO13485:2016 re-certification audits. These certificates cover CytoSorb and our new manufacturing facility commissioned in June 2018. The success of this renewal of the CE Mark and recent audit is a reflection of CytoSorbents‘ ongoing commitment to quality. I am very proud of our quality, manufacturing, and research teams that contributed to these accomplishments.“

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, expands CytoSorb distribution to Brazil, Colombia and Costa Rica, with Contatti Medical, Service & Medical Colombia, and Nutricare Costa Rica, respectively.

Blood poisoning is one of the leading causes of death in Germany. The Bramscher Niels Stensen clinics are now working as one of the first homes in the region with a new method that helps fight blood poisoning as early as possible and save human lives.

The Department of Anaesthesiology, Anesthesiological Intensive Care and Perioperative Pain Management under the direction of Privatdozent Dr. med. med. Gerd Albuszies, MBA in the GPR Clinic, is now using a new therapy method in the intensive care unit of the GPR Clinic, which is used in a massive inflammatory reaction of the body (inflammatory cytokine release) in sepsis.

Every year, up to 20 million people worldwide die of sepsis. That’s up to 13% more than ten years ago. Today, more people are dying of sepsis than total prostate and breast cancer and HIV / AIDS combined.

The therapy of severe blood poisoning – termed Sepsis – is one of the specialties of intensive care at the Klinikum Emden. The Department of Anaesthesiology and Intensive Care Medicine under the direction of chief physician Dr. med. Klaus Kogelmann has long been represented at international congresses with his own work and together with the German working group SepNet (Competence Network Sepsis). For example, at the 7th International Sepsis Congress in Weimar in September, a presentation on the subject of “Blood purification in sepsis” (Cytosorb) was presented.